SLV 332
Alternative Names: Neurokinin 2 antagonist - Solvay; NK-2 antagonist - Solvay; SLV-332Latest Information Update: 20 Jan 2020
At a glance
- Originator ArQule
- Class Irritable bowel syndrome therapies
- Mechanism of Action Neurokinin 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 11 Jul 2007 Discontinued - Preclinical for Irritable bowel syndrome in Europe (unspecified route)
- 29 Sep 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ASC-2006) have been added to the Digestive System Disorders pharmacodynamics section